Company Encyclopedia
View More
name
GYBYS
600332.SH
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, import, and export of Western and Chinese medicines, medical instruments, pharmaceutical products, medical apparatus, and healthcare products; research and development, production, and sale of beverages, food, healthcare products, and other products; and production and sale of pre-packaged food, dairy products, etc., as well as offers herbal tea, tablets, capsules, lozenges, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical services, health management, health preservation and elderly care, etc.; and provides leasing and commercial, health, advertising, loading offloading, and warehouse services.
402.16 B
600332.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care DistributorsIndustry
Industry Ranking5/25
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE8.06%B
    • Profit Margin3.85%C
    • Gross Margin16.17%D
  • Growth ScoreC
    • Revenue YoY1.50%C
    • Net Profit YoY-12.76%D
    • Total Assets YoY4.94%C
    • Net Assets YoY5.07%B
  • Cash ScoreB
    • Cash Flow Margin2596.25%A
    • OCF YoY1.50%C
  • Operating ScoreA
    • Turnover0.95A
  • Debt ScoreC
    • Gearing Ratio51.92%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Guangyao Group established an animal health technology company with a registered capital of 200 million

    According to the Tianyancha App, on October 27, Guangzhou Guangyao Animal Health Technology Co., Ltd. was established, with Liu Yang as the legal representative and a registered capital of 200 million RMB. Its business scope includes agricultural scientific research and experimental development, intelligent agricultural management, and agricultural production hosting services, and it is wholly owned by Guangzhou Shennong Modern Agriculture Co., Ltd., which is a wholly-owned subsidiary of Guangzhou Pharmaceutical Group Co., Ltd

    Zhitong·
    SH
    600332
    +0.31%
    HK
    00874
    +0.37%
    Zhitong·
    SH
    600332
    +0.31%
    HK
    00874
    +0.37%

    Understanding the Market | BAIYUNSHAN PH rose over 4% after earnings, with net profit attributable to shareholders for the first three quarters at 3.31 billion yuan; its Wanglaoji International can product has debuted in the Middle East market

    BAIYUNSHAN PH rose over 4% after earnings, as of the time of writing, up 4.61%, reported at HKD 18.85, with a trading volume of HKD 58.3307 million. On the news front, on October 28, BAIYUNSHAN announced its performance for the first three quarters of 2025, with the group achieving operating revenue of CNY 61.606 billion, an increase of 4.31% year-on-year; net profit attributable to shareholders of the listed company was CNY 3.31 billion, an increase of 4.78% year-on-year; basic earnings per share were CNY 2.036. It is worth mentioning that recently, the Fortune Global Forum opened in Riyadh, the capital of Saudi Arabia. BAIYUNSHAN's Wanglaoji Health was invited to attend and held the Wanglaoji WALOVI international can listing ceremony in Saudi Arabia during the forum. It is reported that after launching the "WALOVI" English brand logo in Saudi Arabia in February this year, Wanglaoji's international can officially listed in Saudi Arabia, marking the first entry of this product series into the Middle Eastern market and representing a key step in Wanglaoji's globalization strategy in the Middle East

    Zhitong·
    SH
    600332
    +0.31%
    HK
    00874
    +0.37%
    Zhitong·
    SH
    600332
    +0.31%
    HK
    00874
    +0.37%

    BAIYUNSHAN PH released its performance for the first three quarters, with a net profit attributable to shareholders of RMB 3.31 billion, an increase of 4.78% year-on-year

    According to the Zhitong Finance APP, BAIYUNSHAN PH released its performance for the first three quarters of 2025, reporting an operating income of 61.606 billion yuan, an increase of 4.31% year-on-year; net profit attributable to shareholders of the listed company was 3.31 billion yuan, an increase of 4.78% year-on-year; basic earnings per share were 2.036 yuan

    Zhitong·
    SH
    600332
    +0.31%
    HK
    00874
    +0.37%
    Zhitong·
    SH
    600332
    +0.31%
    HK
    00874
    +0.37%

    BAIYUNSHAN PH: Third quarter net profit of 794 million yuan, a year-on-year increase of 30.28%

    BAIYUNSHAN PH announced that the revenue for the third quarter was 19.771 billion yuan, a year-on-year increase of 9.74%; the net profit was 794 million yuan, a year-on-year increase of 30.28%. The revenue for the first three quarters was 61.606 billion yuan, a year-on-year increase of 4.31%; the net profit was 3.31 billion yuan, a year-on-year increase of 4.78%

    Zhitong·
    SH
    600332
    +0.31%
    HK
    00874
    +0.37%
    Zhitong·
    SH
    600332
    +0.31%
    HK
    00874
    +0.37%

    BAIYUNSHAN PH: Ke Gan Li Yan Oral Solution enters Phase III clinical trials

    BAIYUNSHAN PH announced that its subsidiary Wanglaoji Pharmaceutical has initiated the Phase III clinical trial of Ke Gan Li Yan oral solution. This drug received its new drug certificate in 1997 and is primarily used for the treatment of acute pharyngitis, with the effects of dispelling wind and clearing heat, detoxifying, and benefiting the throat. Wanglaoji Pharmaceutical obtained clinical trial approval from the National Medical Products Administration in February 2024 and has now officially commenced the relevant trials

    Zhitong·
    SH
    600332
    +0.31%
    HK
    00874
    +0.37%
    Zhitong·
    SH
    600332
    +0.31%
    HK
    00874
    +0.37%
    © 2025 Longbridge｜Disclaimer